1
|
Montero-Pérez-Barquero M, Escobar-Cervantes C, Llàcer P, Quirós-López R, Trullás JC, Cerqueiro JM, Epelde-Gonzálo F, Carrera-Izquierdo M, Formiga F, González-Franco A, Casado-Cerrada J. Projected clinical benefits of dapagliflozin in patients with heart failure with preserved ejection fraction. Future Cardiol 2023; 19:333-342. [PMID: 37382199 DOI: 10.2217/fca-2023-0015] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/30/2023] Open
Abstract
Aims: To address the projected clinical benefits of dapagliflozin among patients with heart failure (HF) with mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF). Methods: A multicenter, prospective, cohort study of patients ≥50 years admitted with HF to Spanish internal medicine departments. The projected clinical benefits of dapagliflozin were calculated from the DELIVER trial. Results: A total of 4049 patients were included; 3271 (80.8%) were eligible for dapagliflozin treatment, according to DELIVER criteria. Within 1 year after discharge, 22.2% were rehospitalized for HF and 21.6% died. Implementation of dapagliflozin would translate into an absolute risk reduction of 1.3% for mortality and 5.1% for HF readmission. Conclusion: HF patients with preserved or mildly reduced ejection fraction have a high risk of events. The use of dapagliflozin could substantially reduce the HF burden.
Collapse
Affiliation(s)
| | | | - Pau Llàcer
- Servicio de Medicina Interna, Hospital Universitario Ramón y Cajal, IRYCIS, 28034, Madrid, Spain
| | - Raúl Quirós-López
- Servicio de Medicina Interna, Hospital de la Costa del Sol, Marbella, 29603, Málaga, Spain
| | - Joan C Trullás
- Internal Medicine Department, Hospital d'Olot, Tissue Repair & Regeneration Laboratory (TR2Lab), Universitat Central de Catalunya, Vic, 17800, Barcelona, Spain
| | - Jose M Cerqueiro
- Servicio de Medicina Interna, Hospital Universitario Lucus Augusti, 27003, Lugo, Spain
| | | | | | - Francesc Formiga
- Internal Medicine Department, Hospital Universitari de Bellvitge, 08907, Barcelona, Spain
| | - Alvaro González-Franco
- Servicio de Medicina Interna, Hospital Universitario Central de Asturias, 33011, Oviedo, Spain
| | - Jesús Casado-Cerrada
- Internal Medicine Department, University Hospital of Getafe, 28905, Madrid, Spain
| |
Collapse
|
2
|
Montero-Pérez-Barquero M, Escobar-Cervantes C, Dávila-Ramos MF, Suárez-Pedreira I, Pérez-Silvestre J, Ceresuela-Eito LM, Muela-Molinero A, Quesada-Simón MA, Formiga F, González-Franco A, Casado-Cerrada J. Benefits of dapagliflozin in the whole spectrum of heart failure in clinical practice: the RICA registry. Future Cardiol 2023; 19:323-332. [PMID: 37382089 DOI: 10.2217/fca-2023-0014] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/30/2023] Open
Abstract
Aims: To determine the projected benefits of dapagliflozin after an acute heart failure (HF) event in Spain. Methods: A multicenter and prospective study that included subjects aged 50 years or older consecutively admitted with HF to internal medicine departments in Spain. The projected clinical benefits of dapagliflozin were calculated via pooled analysis of the DAPA-HF and DELIVER trials. Results: A total of 5644 subjects were analyzed, of whom 79.2% were eligible for dapagliflozin, according to criteria of the DAPA-HF and DELIVER trials. Full implementation of dapagliflozin would imply a 1-year absolute risk reduction of 2.3% for death (number needed to treat = 43) and 5.7% (number needed to treat = 17) for HF rehospitalization. Conclusion: Treatment with dapagliflozin could significantly reduce HF burden in clinical practice.
Collapse
Affiliation(s)
| | | | | | | | - José Pérez-Silvestre
- Internal Medicine, Consorcio Hospital General Universitario de Valencia, 46014, Valencia, Spain
| | | | | | | | - Francesc Formiga
- Internal Medicine Department, Hospital Universitari de Bellvitge, 08907, Barcelona, Spain
| | - Alvaro González-Franco
- Servicio de Medicina Interna, Hospital Universitario Central de Asturias, 33011, Oviedo, Spain
| | - Jesús Casado-Cerrada
- Internal Medicine Department, University Hospital of Getafe, 28905, Madrid, Spain
| |
Collapse
|